The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway

(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions known as RASopathies, raising the important question of how the same mutation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Andreadi, Catherine, Cheung, Lai-Kay, Giblett, Susan, Patel, Bipin, Jin, Hong, Mercer, Kathryn, Kamata, Tamihiro, Lee, Pearl, Williams, Alexander, McMahon, Martin, Marais, Richard, Pritchard, Catrin
Format: Artigo
Sprache:Inglês
Veröffentlicht: Cold Spring Harbor Laboratory Press 2012
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3435497/
https://ncbi.nlm.nih.gov/pubmed/22892241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.193458.112
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge